Our pharmaceutical consulting team is prepared to help your company face some of today’s most pressing challenges.
Companies taking a patient-centered approach are better able to establish personalized connections for their patients and meaningfully engage with them throughout the entire treatment journey.
R&D and Innovation
An inherent challenge for businesses is: how do we fail faster? Investment in R&D, data, and analytics, and talent recruitment will contribute to overall industry innovation for treatment and prevention.
The pharmaceutical field is full of confidential data, from patient records to trial results to patented work; it is absolutely vital to protect this data and IP from any cybersecurity threat.
Global supply chain disruption and API scarcity will force the industry to diversify sourcing locations and establish new supplier networks – all while providing real-time, full-product visibility and traceability.
Transition to Cell and Gene Therapy
The field of cell and gene therapy is evolving quickly and facing continued technological, regulatory, and commercialization hurdles.
Learn More About Our Life Sciences Consulting Practice
Diagnostics Trends Report
Read our annual trends report to stay up-to-date with where the diagnostics industry is headed.Download the 2023 Trends Report
Clinical Trials Trends Report
Read our annual trends report to stay up-to-date with where the clinical trials industry is headed.Download the 2023 Trends Report
Pharmaceutical Trends Report
Read our trends report from a few years back to review key pharma considerations that are still at play in the industry.Download the 2021 Pharmaceutical Trends Report
Preparing for Commercial Launch?
Clarkston supports late-stage clinical companies on their path to commercialization. Leveraging deep industry expertise and recognized functional and business process leadership to help companies transition from development to commercialization, ensuring sustainable, long-term growth.Clinical-Stage and Commercial Launch Services
A Rare Genetic Disease Biopharmaceutical Organization
Prototype to Launch: A Digital Tool to Facilitate Phase 3 Clinical Trials
More than 10,000 rare disease patients referred through the bespoke digital tool
Trained dozens of pharmaceutical executives and leaders on how to successfully and compliantly use the new digital tool to streamline workflows and key processes
Digital tool has been in place for >12 months and successfully used daily by a variety of stakeholders (HCPs, PIs, MSLs, clinical operations, others)